Source: United States & Canada – South China Morning PostAstraZeneca said on Monday its antibody-based cocktail to prevent and treat Covid-19 retained neutralising activity against Omicron coronavirus variants, including the highly contagious BA. 2 sub-variant, in an independent lab study.This is the first data looking at the impact of AstraZeneca’s Evusheld treatment on “cousins” of the Omicron variant following a recent global spike in cases. The Anglo-Swedish drug maker said in December that another lab study found that Evusheld retained…Read More